DexCom, Inc. (DXCM): Price and Financial Metrics

DexCom, Inc. (DXCM)

Today's Latest Price: $396.50 USD

8.66 (2.23%)

Updated Oct 22 2:27pm

Add DXCM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

DXCM Stock Summary

  • Dexcom Inc's market capitalization of $37,132,657,563 is ahead of 94.6% of US-listed equities.
  • With a price/earnings ratio of 181.4, Dexcom Inc P/E ratio is greater than that of about 96.11% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for DXCM is currently 94.2, higher than 96.25% of US stocks with positive operating cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Dexcom Inc are ANSS, YNDX, ILMN, TTD, and NTES.
  • DXCM's SEC filings can be seen here. And to visit Dexcom Inc's official web site, go to

DXCM Stock Price Chart Interactive Chart >

Price chart for DXCM

DXCM Price/Volume Stats

Current price $396.50 52-week high $456.23
Prev. close $387.84 52-week low $145.23
Day low $385.86 Volume 303,573
Day high $398.25 Avg. volume 1,234,794
50-day MA $405.05 Dividend yield N/A
200-day MA $349.41 Market Cap 37.96B

DexCom, Inc. (DXCM) Company Bio

DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.

DXCM Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$396.50$361.57 -8%

Below please find a table outlining a discounted cash flow forecast for DXCM, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dexcom Inc ranked in the 45th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for DXCM, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 96. Its equity weight surpasses that of 74.34% of free cash flow generating stocks in the Healthcare sector.
  • The company's compound free cash flow growth rate over the past 5.42 years comes in at 0.85%; that's greater than 89% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 14.11% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Dexcom Inc? See AMED, MEDP, MCK, USPH, and HBIO.

DXCM Latest News Stream

Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream

Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about Dexcom Inc that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Wearable Injectors Market 2020 Research and New Innovations in Medical Sector- Amgen, Becton, Dickinson and Company, Dexcom, Insulet Corporation

Oct 02, 2020 (Market Insight Reports) -- This Global Wearable Injectors Market Research Report Forecast 2020-2025 is a valuable source of insightful data for…

MarketWatch | October 2, 2020

Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time

Business Wire | October 1, 2020

Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

SAN DIEGO--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

Business Wire | September 22, 2020

Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic

SAN DIEGO--(BUSINESS WIRE)--Dexcom announces first-ever registry dedicated to tracking outcomes of in-hospital real-time CGM use in response to the COVID-19 pandemic

Business Wire | September 16, 2020

Dexcom Appoints Karen Dahut to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Karen Dahut to Board of Directors

Business Wire | August 12, 2020

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo -0.41%
3-mo -5.99%
6-mo 19.27%
1-year 170.72%
3-year 785.64%
5-year 380.61%
YTD 81.27%
2019 82.59%
2018 108.75%
2017 -3.87%
2016 -27.11%
2015 48.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7608 seconds.